Puma Biotechnology (PBYI) Equity Average (2011 - 2026)

Puma Biotechnology has reported Equity Average for 16 years, with the latest figure at $129.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 36.74% year-over-year to $129.4 million; the trailing twelve-month figure through Mar 2026 stood at $129.4 million (up 36.74% YoY), and the FY2025 full-year result was $111.2 million, up 52.83% from the prior year.
• Equity Average for Q1 2026 stood at $129.4 million, up from $122.8 million in the prior quarter.
• The five-year high for Equity Average was $129.4 million in Q1 2026, with the low at $2.3 million in Q1 2022.
• Historically, Equity Average has averaged $58.4 million across 5 years, with a median of $49.7 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average sank 54.76% — and 2023, when it soared 909.9%.
• Puma Biotechnology's Equity Average stood at $21.9 million in 2022, then jumped by 110.64% to $46.1 million in 2023, then jumped by 77.05% to $81.6 million in 2024, then soared by 50.48% to $122.8 million in 2025, then rose by 5.35% to $129.4 million in 2026.
• The last three Equity Average figures came in at $129.4 million (Q1 2026), $122.8 million (Q4 2025), and $110.0 million (Q3 2025), per Business Quant data.